Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Preferred Stock Liabilities (2021)

bioAffinity Technologies has reported Preferred Stock Liabilities over the past 1 years, most recently at $4.0 million for Q4 2021.

  • Quarterly Preferred Stock Liabilities changed N/A to $4.0 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2021, changed N/A year-over-year, with the annual reading at $4.0 million for FY2021, N/A changed from the prior year.
  • Preferred Stock Liabilities was $4.0 million for Q4 2021 at bioAffinity Technologies.
  • Over five years, Preferred Stock Liabilities peaked at $4.0 million in Q4 2021 and troughed at $4.0 million in Q4 2021.